Amplion Teams with Built Oregon to Publish First Podcast

The team at Amplion, inventors of BiomarkerBase, is proud to share a podcast we did with Making Oregon – the podcast that brings conversations with innovators, makers, doers, disruptors, and groundbreakers across the state. Take a listen to the story behind...

Chart of the Week: Hepatitis C – Gilead Wins

In honor of Gilead’s newly approved, and cheaper, hepatitis C drug we decided to show the biomarker, trial and company landscape for hepatitis C. You can read more about Gilead’s new drug here, here and here. Purple: Company Red: Trials Blue: Biomarkers...

LDT Companies Out-Perform IVD Companies

Last week we posted an analysis of the growth rates and market caps for companies that develop IVD tests (which was in itself a follow-up to some analyses from a couple of years ago).  This week we are presenting the same analysis for developers of lab-developed tests...

Chart of the Week: Value Network of Healthcare

We are mildly obssessed with our customers and the markets into which we sell BiomarkerBase™.  We have been thinking lately about the value chain in healthcare and have concluded that, like most industries, it’s quite complicated.  We have tried to represent the...

Dx Test Developers Experience Declining Revenue Growth

The news this week that CMS may reduce rates for some molecular diagnostic tests (by over 70% in a couple of cases) stimulated the idea of taking a quick look at the current market dynamics for diagnostic test developers. For this week’s post we decided to...